These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 35693455)
1. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Anugwom CM; Leventhal TM; Debes JD Hepatoma Res; 2022; 8():. PubMed ID: 35693455 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors? Jiang J; Huang H; Chen R; Lin Y; Ling Q Front Immunol; 2023; 14():1092401. PubMed ID: 36875077 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in liver transplant: a case series. Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081 [TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699 [TBL] [Abstract][Full Text] [Related]
5. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. Rezaee-Zavareh MS; Yeo YH; Wang T; Guo Z; Tabrizian P; Ward SC; Barakat F; Hassanein TI; Dave S; Ajmera V; Bhoori S; Mazzaferro V; Chascsa DMH; Liu MC; Aby ES; Lake JR; Sogbe M; Sangro B; Abdelrahim M; Esmail A; Schmiderer A; Chouik Y; Rudolph M; Sohal D; Giudicelli H; Allaire M; Akce M; Guadagno J; Tow CY; Massoumi H; De Simone P; Kang E; Gartrell RD; Martinez M; Paz-Fumagalli R; Toskich BB; Tran NH; Solino GA; Poltronieri Pacheco DM; Kalman RS; Agopian VG; Mehta N; Parikh ND; Singal AG; Yang JD J Hepatol; 2025 Jan; 82(1):107-119. PubMed ID: 38996924 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and transplantation for hepatocellular carcinoma. Tabrizian P; Abdelrahim M; Schwartz M J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289 [TBL] [Abstract][Full Text] [Related]
7. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549 [TBL] [Abstract][Full Text] [Related]
8. Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. De Stefano N; Patrono D; Colli F; Rizza G; Paraluppi G; Romagnoli R Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001436 [TBL] [Abstract][Full Text] [Related]
9. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533 [TBL] [Abstract][Full Text] [Related]
10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
11. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Bai J; Liang P; Li Q; Feng R; Liu J Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis. Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022 [TBL] [Abstract][Full Text] [Related]
13. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417 [TBL] [Abstract][Full Text] [Related]
14. Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Dehghan Y; Schnickel GT; Hosseini M; Burgoyne AM; Ajmera VH; Morris GP; Mendler MH; Parekh JR; Abushamat F; Vodkin I; Kono Y Clin J Gastroenterol; 2021 Dec; 14(6):1718-1724. PubMed ID: 34643885 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy before liver transplant in unresectable hepatocellular carcinoma: a case report. Ohm H; Khwaja R; Karachiwala H J Gastrointest Oncol; 2023 Dec; 14(6):2644-2649. PubMed ID: 38196545 [TBL] [Abstract][Full Text] [Related]
16. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials. Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542 [TBL] [Abstract][Full Text] [Related]
18. Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors. Lin Z; Lu D; Wei X; Wang J; Xu X Am J Cancer Res; 2020; 10(4):1085-1102. PubMed ID: 32368387 [TBL] [Abstract][Full Text] [Related]
19. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma. Yin X; Wu T; Lan Y; Yang W Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482 [TBL] [Abstract][Full Text] [Related]